Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues
Reexamination Certificate
1999-04-28
2001-04-10
Kunz, Gary L. (Department: 1646)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
C435S069100, C435S070100, C435S071100, C435S071200, C435S252300, C435S320100, C435S325000, C435S471000
Reexamination Certificate
active
06214972
ABSTRACT:
BACKGROUND OF THE INVENTION
Prostaglandin D
2
(PGD
2
) is synthesized in a number of tissues including brain, spleen, lung, mast cells, bone marrow, stomach, skin and eye (Negishi M., et al., Prog. Lipid Res. 32:417-434, 1993, and references within). Central nervous system actions of PGD
2
are thought to involve effects on sleep induction, body temperature, olfactory function, hormone release, inflammation and analgesia (Negishi M., et al., supra, and references within). PGD
2
can cause inhibition of platelet aggregation (Coleman R. A., et al., Pharmacological Reviews 46:205-229, 1994, and references within). PGD
2
is also the predominant prostanoid released from mast cells upon immunologic challenge and as such is thought to be a mediator of various allergic disorders including but not limited to allergic rhinitis and airway hyperreactivity (Ito S. et al., Prostaglandins Leukotrienes and Essential Fatty Acids. 37:219-234, 1989, and references within). It may also stimulate secretion in the intestine. Topically applied PGD
2
has also been shown to reduce intraoccular pressure (Woodward D. F., et al. European J. Pharmacology. 230:327-333, 1993, and Nakajima M., et al., Graefe's Arch. Clin. Exp. Ophthalmol. 229:411-413, 1991).
The physiological actions of PGD
2
are mediated through interaction with the prostanoid DP receptor. The DP receptors are thought to be distributed mainly in blood platelets, smooth muscle of various tissues and nervous tissue, including the central nervous system (Coleman R. A., et al., supra, and references within). However, the DP receptor is the least ubiquitous and least abundant of the prostanoid receptors and as such is the one least well characterized. To further complicate matters many of the actions of PGD
2
and distribution of their receptor are also species dependent. Specific binding sites for the DP receptor have been tentatively studied using human platelet membranes, rat brain synaptic membranes and membranes prepared from a cell line derived from bovine embryonic trachea (Coleman R. A., et al., supra, and references within).
The above methods for studying DP receptor activities have several disadvantages in that most if not all preparations contain several different but related prostanoid receptor populations, each with different ligand binding properties, making measurements of absolute potency and selectivity very unpredictable. In addition, the low abundance of the DP receptor in various tissues or cells makes it very difficult to satisfactorily test for compounds as modulators, effectors, agonists or antagonists, of the human DP receptor.
SUMMARY OF THE INVENTION
A novel prostaglandin receptor protein termed DP has been identified from human cells. A DNA molecule encoding the full length DP protein has been isolated and purified, and the nucleotide sequence has been determined. The DP encoding DNA has been cloned into expression vectors and these expression vectors, when introduced into recombinant host cells, cause the recombinant host cells to express a functional DP receptor protein. The novel DP protein, the DP-encoding DNA, the expression vectors and recombinant host cells expressing recombinant DP are useful in the identification of modulators of DP receptor activity.
A method of identifying DP receptor modulators is also disclosed which utilizes the recombinant DP expressing host cells. Modulators of DP activity are useful for the treatment of prostaglandin-related diseases and for modulating the effects of prostaglandins on the DP receptor.
REFERENCES:
patent: 5516652 (1996-05-01), Abramovitz
patent: 5605814 (1997-02-01), Abramovitz
patent: 5869281 (1999-02-01), Abramovitz
patent: 5985597 (1999-11-01), Ford-Hutchinson
patent: WO 94/28125 (1994-12-01), None
patent: WO 95/00551 (1995-01-01), None
patent: WO 95/00552 (1995-01-01), None
Csepli J. and Csapo Al. The effect of the prostaglandin F2a analogue ICI 81008 on uterine small arteries and on blood pressure. Prostaglandins. vol. 10, pp. 689-697, 1975.*
Davis J. et al. Prostaglandin F2a stimulates phosphatidylinositol 4,5-bisphosphate hydrolysis and mobilizes intracellular Ca2+ in bovine luteal cells. Proc. Natl. Acad. Sci. USA. vol. 84, pp. 3728-3732, 1987.*
Black F. and Wakeman M. Activation of inositol phospholipid breakdown by prostglandin F2a without any stimulation of proliferation in quiescent NIH-3T3 fibroblasts. Biochem. J. vol. 266, pp. 661-667, 1990.*
Rangachari et al. ‘Effects of a Selective DP Receptor Agonists (BW 245C) . . . An Argument for a Different DP Receptor’, Jour. of Pharm. and Experimental Thera. Vo. 275, No. 2, (1995) pp. 611-617.
R. Coleman, et al., Characterisation Of The Prostanoid Receptors Mediating Contraction of Guinea-Pig Isolated Trachea, (1985), Prostaglandins, 29, pp. 363-375.
P. Davies, et. al., Prostaglandins and Inflammation, (1992), Inflammation: Basic Principles And Clinical Correlates, Gallin, Goldstein, Snyderman, eds., 2nd Ed., pp. 123-138.
E. Horton, et al., Uterine Luteolytic Hormone: A Physiological Role for Prostaglandin F2a, (1976), Physiol. Rev., 56, pp. 595-651.
D. DeWitt, Prostaglandin endoperoxide synthase: regulation of enzyme expression, (1991), Biochim. Biophys, Acta, 1083, pp. 121-134.
J. Stjernschantz, et al., Phenyl substituted prostaglandin analogs for glaucoma treatment, (1992), Drugs Future, 17, pp. 691-704.
P. Racz, et al., Maintained Intraocular Pressure Reduction With Once-a-Day Application of a New Prostaglandin F2a Analogue (PhXA41), (1993), Arch. Opthalmol., 111, pp. 657-661.
J. Senior, et al., In vitro characterization of prostanoid FP-, DP-, IP- and TP-receptors on the non-pregnant human myometrium, (1992), Brit. J. Pharmacol., 107, pp. 215-221.
J. Senior, et al., In vitro characterization of prostanoid receptors on human myometrium at term pregnancy, (1993), Brit. J. Pharmacol., 108, pp. 501-506.
J. Csepli, et al., The Effect Of The Prostaglandin F2a Analogue ICI 81008 On Uterine SMall Artenes And On Blood Pressure, (1975), Prostaglandins, 10, pp. 689-697.
R. Coleman, Methods in prostanoid receptor classification, (1987), Prostaglandins And Related Substances -A Practical Approach, IRL PRess, 1st Ed., pp. 267-303.
R. Coleman, et al., A study of the prostanoid receptors mediating bronchocorstriction in the anaesthetized guinea-pig and dog, (1981), Brit. J. Pharmacol., 74, pp. 913-914.
J. Barnard, et al., Evaluation of prostaglandin F2a and prostacyclin interactions in the isolated perfused rat lung, (1992), J. Appl. Physiol., 72, pp. 2469-2474.
J. Davis et al., Prostaglandin F2a stimulates phosphatidylinositol 4,5-bisphosphate hydrolysis and mobilizes intracellular Ca2+ in bovine luteal cells, (1987), Proc. Natl. Acad. Sci. U.S.A., 84 pp. 3728-3732.
J. Kitanaka, et al., Astrocytes Possess Prostaglandin F2a Receptors Coupled To Phospholipase C, (1991), Biochem. Biophys. Res. Comm., 178, pp. 946-952.
F. Black, et al., Activation of inositol phospholipid breakdown by prostaglandin F2a without any simulation of proliferation in quiescent NIH-3T3 fibroblasts, (1990), Biochem. Journal, 266, pp. 661-667.
A. Nakao, et al., Characterization of Prostaglandin F2a Receptor of Mouse 3T3 Fibroblasts and Its Functional Expression in Xenopus Laevis Oocytes, (1993), J. Cell Physiol., 155, pp. 257-264.
W. Powell, et al., Prostaglandin F2a Receptor in Ovine corpora lutea, (1974), Eur. J. Biochem., 41, pp. 103-107.
W. Powell, et al., Occurrence and Properties of a Prostaglandin F2a Receptor in Bovine Corpora Lutea, (1975), Eur. J. Biochem., 56, pp. 73-77.
W. Powell, et al., Localization of a Prostaglandin F2a Receptor in Bovine Corpus luteum Plasma Membranes, (1976), Eur. J. Biochem., 61, pp. 605-611.
M. Molnar, et al., PGF2a and PGE2 binding to rat myometrium during gestation, parturition, and postpartum, (1990), Am. J. Physiol., 258, pp. E740-E747.
Th. Bauknecht, et al., Distribution of prostaglandin E2 and prostaglandin F2a receptors in human myometrium, (1981), Acta Endocrinol., 98, pp. 446-450.
F. Neuschafer-Rube, et al., Characterization of prostaglandin-F2a-binding sites on rat hepatocyte plasma me
Abramovitz Mark
Boie Yves
Metters Kathleen
Sawyer Nicole
Slipetz Deborah M.
Hand J. Mark
Kunz Gary L.
Landsman Robert
Merck Frosst Canada & Co.
Tribble Jack L.
LandOfFree
DNA encoding prostaglandin receptor DP does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with DNA encoding prostaglandin receptor DP, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and DNA encoding prostaglandin receptor DP will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2525551